XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Stock Information for Bionik Laboratories Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bionik Laboratories Corp

XOMA Royalty Enters into Agreement to Acquire Generation Bio
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.